{
  "symbol": "DXCM",
  "company_name": "Dexcom Inc",
  "ir_website": "https://investors.dexcom.com/",
  "structured_data": [
    {
      "section_name": "News Articles",
      "links": [
        {
          "title": "Dexcom Announces New Partnership for Enhanced Diabetes Management Solutions",
          "url": "https://investors.dexcom.com/newsroom/news-articles/partnership-2024",
          "content": "[Skip to main content](#maincontent)\n\n[![Dexcom Logo](//s201.q4cdn.com/758408164/files/design/assets/Dexcom-Logo_IR-Website.png)](https://www.dexcom.com/)\n\n[About Dexcom](https://www.dexcom.com/about-dexcom) [Careers](https://careers.dexcom.com/careers) [Media Kit](https://www.dexcom.com/media-kit)\n\n![search icon](//s201.q4cdn.com/758408164/files/design/svg/mobile-search-icon.svg)\n\nSearch query \n\n# Page Not Found\n\n## Site Map\n\nWe're sorry, but there is no page on the site that matches your entry. It is possible you typed the address incorrectly, or the page may no longer exist. You may wish to try another entry or choose from the links below, which we hope will help you find what you are looking for.\n\nIf you believe that this page should exist, please send an email to support@q4inc.com explaining the page you were trying to access.\n\nThanks for your patience, understanding, and help.\n\n[![dexcom logo](//s201.q4cdn.com/758408164/files/design/svg/dexcom-logo-white.svg)](https://www.dexcom.com/)\n\nFollow us\n\n[![facebook icon](//s201.q4cdn.com/758408164/files/design/svg/f.svg)](https://www.facebook.com/dexcom) [![linkedin icon](//s201.q4cdn.com/758408164/files/design/svg/LinkedIn.svg)](https://www.linkedin.com/company/dexcom) [![youtube icon](//s201.q4cdn.com/758408164/files/design/svg/youtube-\\(1\\).svg)](https://www.youtube.com/user/dexcomCGM)\n\n### IR Contacts\n\nSean Christensen\n\nVice President, Finance and Investor Relations\n\nMatt Carey\n\nSenior Investor Relations Manager\n\n[(858) 200-0200](tel:858-200-0200) investor-relations@dexcom.com\n\n## Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt DexCom, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to DexCom, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \nEnd of Day Stock Quote  \nEvents & Presentations  \n  \nSubmit Sign Up\n\n[Unsubscribe](/resources/investor-email-alerts/#unsubscribe)\n\n## Email Alert Sign Up Confirmation\n\n1. JAMA. 2017;317(4):371-378. 2. Welsh, J.B. et al (2019). \"Accuracy, Utilization, and Effectiveness Comparisons of Different Continuous Glucose Monitoring Systems.\" Diabetes Technol Ther 21(3) Dexcom, Dexcom G6, Dexcom Share, and Dexcom CLARITY are registered trademarks of Dexcom, Inc. in the United States and/or other countries.\n\n*If your glucose alerts and readings from the G6 or G7 CGM Systems do not match symptoms or expectations or you’re taking over the recommended maximum dosage amount of 1000mg of acetaminophen every 6 hours, use a blood glucose meter to make diabetes treatment decisions.\n\n  * [Privacy Policy](https://www.dexcom.com/linked/documentservice/PrivacyPolicy)\n  * [Terms of Use](https://www.dexcom.com/linked/documentservice/TermsOfUse)\n\n\n\n© 2024 Q4 Inc. - All rights reserved \n\n[ Powered By Q4 Inc. 5.140.1.1 (opens in new window) ](https://www.q4inc.com/Powered-by-Q4/)\n"
        },
        {
          "title": "Dexcom Reports Strong Q1 2024 Results",
          "url": "https://investors.dexcom.com/newsroom/news-articles/q1-2024-results",
          "content": "[Skip to main content](#maincontent)\n\n[![Dexcom Logo](//s201.q4cdn.com/758408164/files/design/assets/Dexcom-Logo_IR-Website.png)](https://www.dexcom.com/)\n\n[About Dexcom](https://www.dexcom.com/about-dexcom) [Careers](https://careers.dexcom.com/careers) [Media Kit](https://www.dexcom.com/media-kit)\n\n![search icon](//s201.q4cdn.com/758408164/files/design/svg/mobile-search-icon.svg)\n\nSearch query \n\n# Page Not Found\n\n## Site Map\n\nWe're sorry, but there is no page on the site that matches your entry. It is possible you typed the address incorrectly, or the page may no longer exist. You may wish to try another entry or choose from the links below, which we hope will help you find what you are looking for.\n\nIf you believe that this page should exist, please send an email to support@q4inc.com explaining the page you were trying to access.\n\nThanks for your patience, understanding, and help.\n\n[![dexcom logo](//s201.q4cdn.com/758408164/files/design/svg/dexcom-logo-white.svg)](https://www.dexcom.com/)\n\nFollow us\n\n[![facebook icon](//s201.q4cdn.com/758408164/files/design/svg/f.svg)](https://www.facebook.com/dexcom) [![linkedin icon](//s201.q4cdn.com/758408164/files/design/svg/LinkedIn.svg)](https://www.linkedin.com/company/dexcom) [![youtube icon](//s201.q4cdn.com/758408164/files/design/svg/youtube-\\(1\\).svg)](https://www.youtube.com/user/dexcomCGM)\n\n### IR Contacts\n\nSean Christensen\n\nVice President, Finance and Investor Relations\n\nMatt Carey\n\nSenior Investor Relations Manager\n\n[(858) 200-0200](tel:858-200-0200) investor-relations@dexcom.com\n\n## Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt DexCom, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to DexCom, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \nEnd of Day Stock Quote  \nEvents & Presentations  \n  \nSubmit Sign Up\n\n[Unsubscribe](/resources/investor-email-alerts/#unsubscribe)\n\n## Email Alert Sign Up Confirmation\n\n1. JAMA. 2017;317(4):371-378. 2. Welsh, J.B. et al (2019). \"Accuracy, Utilization, and Effectiveness Comparisons of Different Continuous Glucose Monitoring Systems.\" Diabetes Technol Ther 21(3) Dexcom, Dexcom G6, Dexcom Share, and Dexcom CLARITY are registered trademarks of Dexcom, Inc. in the United States and/or other countries.\n\n*If your glucose alerts and readings from the G6 or G7 CGM Systems do not match symptoms or expectations or you’re taking over the recommended maximum dosage amount of 1000mg of acetaminophen every 6 hours, use a blood glucose meter to make diabetes treatment decisions.\n\n  * [Privacy Policy](https://www.dexcom.com/linked/documentservice/PrivacyPolicy)\n  * [Terms of Use](https://www.dexcom.com/linked/documentservice/TermsOfUse)\n\n\n\n© 2024 Q4 Inc. - All rights reserved \n\n[ Powered By Q4 Inc. 5.140.1.1 (opens in new window) ](https://www.q4inc.com/Powered-by-Q4/)\n"
        }
      ]
    },
    {
      "section_name": "Financial Reports",
      "links": [
        {
          "title": "Q1 2024 Financial Report",
          "url": "https://investors.dexcom.com/financial-reports/q1-2024",
          "content": "[Skip to main content](#maincontent)\n\n[![Dexcom Logo](//s201.q4cdn.com/758408164/files/design/assets/Dexcom-Logo_IR-Website.png)](https://www.dexcom.com/)\n\n[About Dexcom](https://www.dexcom.com/about-dexcom) [Careers](https://careers.dexcom.com/careers) [Media Kit](https://www.dexcom.com/media-kit)\n\n![search icon](//s201.q4cdn.com/758408164/files/design/svg/mobile-search-icon.svg)\n\nSearch query \n\n# Page Not Found\n\n## Site Map\n\nWe're sorry, but there is no page on the site that matches your entry. It is possible you typed the address incorrectly, or the page may no longer exist. You may wish to try another entry or choose from the links below, which we hope will help you find what you are looking for.\n\nIf you believe that this page should exist, please send an email to support@q4inc.com explaining the page you were trying to access.\n\nThanks for your patience, understanding, and help.\n\n[![dexcom logo](//s201.q4cdn.com/758408164/files/design/svg/dexcom-logo-white.svg)](https://www.dexcom.com/)\n\nFollow us\n\n[![facebook icon](//s201.q4cdn.com/758408164/files/design/svg/f.svg)](https://www.facebook.com/dexcom) [![linkedin icon](//s201.q4cdn.com/758408164/files/design/svg/LinkedIn.svg)](https://www.linkedin.com/company/dexcom) [![youtube icon](//s201.q4cdn.com/758408164/files/design/svg/youtube-\\(1\\).svg)](https://www.youtube.com/user/dexcomCGM)\n\n### IR Contacts\n\nSean Christensen\n\nVice President, Finance and Investor Relations\n\nMatt Carey\n\nSenior Investor Relations Manager\n\n[(858) 200-0200](tel:858-200-0200) investor-relations@dexcom.com\n\n## Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt DexCom, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to DexCom, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \nEnd of Day Stock Quote  \nEvents & Presentations  \n  \nSubmit Sign Up\n\n[Unsubscribe](/resources/investor-email-alerts/#unsubscribe)\n\n## Email Alert Sign Up Confirmation\n\n1. JAMA. 2017;317(4):371-378. 2. Welsh, J.B. et al (2019). \"Accuracy, Utilization, and Effectiveness Comparisons of Different Continuous Glucose Monitoring Systems.\" Diabetes Technol Ther 21(3) Dexcom, Dexcom G6, Dexcom Share, and Dexcom CLARITY are registered trademarks of Dexcom, Inc. in the United States and/or other countries.\n\n*If your glucose alerts and readings from the G6 or G7 CGM Systems do not match symptoms or expectations or you’re taking over the recommended maximum dosage amount of 1000mg of acetaminophen every 6 hours, use a blood glucose meter to make diabetes treatment decisions.\n\n  * [Privacy Policy](https://www.dexcom.com/linked/documentservice/PrivacyPolicy)\n  * [Terms of Use](https://www.dexcom.com/linked/documentservice/TermsOfUse)\n\n\n\n© 2024 Q4 Inc. - All rights reserved \n\n[ Powered By Q4 Inc. 5.140.1.1 (opens in new window) ](https://www.q4inc.com/Powered-by-Q4/)\n"
        },
        {
          "title": "Annual Report 2023",
          "url": "https://investors.dexcom.com/financial-reports/annual-report-2023",
          "content": "[Skip to main content](#maincontent)\n\n[![Dexcom Logo](//s201.q4cdn.com/758408164/files/design/assets/Dexcom-Logo_IR-Website.png)](https://www.dexcom.com/)\n\n[About Dexcom](https://www.dexcom.com/about-dexcom) [Careers](https://careers.dexcom.com/careers) [Media Kit](https://www.dexcom.com/media-kit)\n\n![search icon](//s201.q4cdn.com/758408164/files/design/svg/mobile-search-icon.svg)\n\nSearch query \n\n# Page Not Found\n\n## Site Map\n\nWe're sorry, but there is no page on the site that matches your entry. It is possible you typed the address incorrectly, or the page may no longer exist. You may wish to try another entry or choose from the links below, which we hope will help you find what you are looking for.\n\nIf you believe that this page should exist, please send an email to support@q4inc.com explaining the page you were trying to access.\n\nThanks for your patience, understanding, and help.\n\n[![dexcom logo](//s201.q4cdn.com/758408164/files/design/svg/dexcom-logo-white.svg)](https://www.dexcom.com/)\n\nFollow us\n\n[![facebook icon](//s201.q4cdn.com/758408164/files/design/svg/f.svg)](https://www.facebook.com/dexcom) [![linkedin icon](//s201.q4cdn.com/758408164/files/design/svg/LinkedIn.svg)](https://www.linkedin.com/company/dexcom) [![youtube icon](//s201.q4cdn.com/758408164/files/design/svg/youtube-\\(1\\).svg)](https://www.youtube.com/user/dexcomCGM)\n\n### IR Contacts\n\nSean Christensen\n\nVice President, Finance and Investor Relations\n\nMatt Carey\n\nSenior Investor Relations Manager\n\n[(858) 200-0200](tel:858-200-0200) investor-relations@dexcom.com\n\n## Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt DexCom, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to DexCom, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \nEnd of Day Stock Quote  \nEvents & Presentations  \n  \nSubmit Sign Up\n\n[Unsubscribe](/resources/investor-email-alerts/#unsubscribe)\n\n## Email Alert Sign Up Confirmation\n\n1. JAMA. 2017;317(4):371-378. 2. Welsh, J.B. et al (2019). \"Accuracy, Utilization, and Effectiveness Comparisons of Different Continuous Glucose Monitoring Systems.\" Diabetes Technol Ther 21(3) Dexcom, Dexcom G6, Dexcom Share, and Dexcom CLARITY are registered trademarks of Dexcom, Inc. in the United States and/or other countries.\n\n*If your glucose alerts and readings from the G6 or G7 CGM Systems do not match symptoms or expectations or you’re taking over the recommended maximum dosage amount of 1000mg of acetaminophen every 6 hours, use a blood glucose meter to make diabetes treatment decisions.\n\n  * [Privacy Policy](https://www.dexcom.com/linked/documentservice/PrivacyPolicy)\n  * [Terms of Use](https://www.dexcom.com/linked/documentservice/TermsOfUse)\n\n\n\n© 2024 Q4 Inc. - All rights reserved \n\n[ Powered By Q4 Inc. 5.140.1.1 (opens in new window) ](https://www.q4inc.com/Powered-by-Q4/)\n"
        }
      ]
    },
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "Dexcom Launches New Product Line",
          "url": "https://investors.dexcom.com/press-releases/new-product-line-2024",
          "content": "[Skip to main content](#maincontent)\n\n[![Dexcom Logo](//s201.q4cdn.com/758408164/files/design/assets/Dexcom-Logo_IR-Website.png)](https://www.dexcom.com/)\n\n[About Dexcom](https://www.dexcom.com/about-dexcom) [Careers](https://careers.dexcom.com/careers) [Media Kit](https://www.dexcom.com/media-kit)\n\n![search icon](//s201.q4cdn.com/758408164/files/design/svg/mobile-search-icon.svg)\n\nSearch query \n\n# Page Not Found\n\n## Site Map\n\nWe're sorry, but there is no page on the site that matches your entry. It is possible you typed the address incorrectly, or the page may no longer exist. You may wish to try another entry or choose from the links below, which we hope will help you find what you are looking for.\n\nIf you believe that this page should exist, please send an email to support@q4inc.com explaining the page you were trying to access.\n\nThanks for your patience, understanding, and help.\n\n[![dexcom logo](//s201.q4cdn.com/758408164/files/design/svg/dexcom-logo-white.svg)](https://www.dexcom.com/)\n\nFollow us\n\n[![facebook icon](//s201.q4cdn.com/758408164/files/design/svg/f.svg)](https://www.facebook.com/dexcom) [![linkedin icon](//s201.q4cdn.com/758408164/files/design/svg/LinkedIn.svg)](https://www.linkedin.com/company/dexcom) [![youtube icon](//s201.q4cdn.com/758408164/files/design/svg/youtube-\\(1\\).svg)](https://www.youtube.com/user/dexcomCGM)\n\n### IR Contacts\n\nSean Christensen\n\nVice President, Finance and Investor Relations\n\nMatt Carey\n\nSenior Investor Relations Manager\n\n[(858) 200-0200](tel:858-200-0200) investor-relations@dexcom.com\n\n## Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt DexCom, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to DexCom, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \nEnd of Day Stock Quote  \nEvents & Presentations  \n  \nSubmit Sign Up\n\n[Unsubscribe](/resources/investor-email-alerts/#unsubscribe)\n\n## Email Alert Sign Up Confirmation\n\n1. JAMA. 2017;317(4):371-378. 2. Welsh, J.B. et al (2019). \"Accuracy, Utilization, and Effectiveness Comparisons of Different Continuous Glucose Monitoring Systems.\" Diabetes Technol Ther 21(3) Dexcom, Dexcom G6, Dexcom Share, and Dexcom CLARITY are registered trademarks of Dexcom, Inc. in the United States and/or other countries.\n\n*If your glucose alerts and readings from the G6 or G7 CGM Systems do not match symptoms or expectations or you’re taking over the recommended maximum dosage amount of 1000mg of acetaminophen every 6 hours, use a blood glucose meter to make diabetes treatment decisions.\n\n  * [Privacy Policy](https://www.dexcom.com/linked/documentservice/PrivacyPolicy)\n  * [Terms of Use](https://www.dexcom.com/linked/documentservice/TermsOfUse)\n\n\n\n© 2024 Q4 Inc. - All rights reserved \n\n[ Powered By Q4 Inc. 5.140.1.1 (opens in new window) ](https://www.q4inc.com/Powered-by-Q4/)\n"
        },
        {
          "title": "Investor Day 2024 Announcement",
          "url": "https://investors.dexcom.com/press-releases/investor-day-2024",
          "content": "[Skip to main content](#maincontent)\n\n[![Dexcom Logo](//s201.q4cdn.com/758408164/files/design/assets/Dexcom-Logo_IR-Website.png)](https://www.dexcom.com/)\n\n[About Dexcom](https://www.dexcom.com/about-dexcom) [Careers](https://careers.dexcom.com/careers) [Media Kit](https://www.dexcom.com/media-kit)\n\n![search icon](//s201.q4cdn.com/758408164/files/design/svg/mobile-search-icon.svg)\n\nSearch query \n\n# Page Not Found\n\n## Site Map\n\nWe're sorry, but there is no page on the site that matches your entry. It is possible you typed the address incorrectly, or the page may no longer exist. You may wish to try another entry or choose from the links below, which we hope will help you find what you are looking for.\n\nIf you believe that this page should exist, please send an email to support@q4inc.com explaining the page you were trying to access.\n\nThanks for your patience, understanding, and help.\n\n[![dexcom logo](//s201.q4cdn.com/758408164/files/design/svg/dexcom-logo-white.svg)](https://www.dexcom.com/)\n\nFollow us\n\n[![facebook icon](//s201.q4cdn.com/758408164/files/design/svg/f.svg)](https://www.facebook.com/dexcom) [![linkedin icon](//s201.q4cdn.com/758408164/files/design/svg/LinkedIn.svg)](https://www.linkedin.com/company/dexcom) [![youtube icon](//s201.q4cdn.com/758408164/files/design/svg/youtube-\\(1\\).svg)](https://www.youtube.com/user/dexcomCGM)\n\n### IR Contacts\n\nSean Christensen\n\nVice President, Finance and Investor Relations\n\nMatt Carey\n\nSenior Investor Relations Manager\n\n[(858) 200-0200](tel:858-200-0200) investor-relations@dexcom.com\n\n## Investor Email Alerts\n\nTo opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.\n\nAt DexCom, Inc. we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.\n\n**By providing your email address below, you are providing consent to DexCom, Inc. to send you the requested Investor Email Alert updates.**\n\n* Required\n\nEmail Address *  \n---  \nInvestor Alert Options Investor Alert Options *  \n---  \n| News  \n---  \nQuarterly Reports  \nAnnual Reports  \nSEC Filings  \nEnd of Day Stock Quote  \nEvents & Presentations  \n  \nSubmit Sign Up\n\n[Unsubscribe](/resources/investor-email-alerts/#unsubscribe)\n\n## Email Alert Sign Up Confirmation\n\n1. JAMA. 2017;317(4):371-378. 2. Welsh, J.B. et al (2019). \"Accuracy, Utilization, and Effectiveness Comparisons of Different Continuous Glucose Monitoring Systems.\" Diabetes Technol Ther 21(3) Dexcom, Dexcom G6, Dexcom Share, and Dexcom CLARITY are registered trademarks of Dexcom, Inc. in the United States and/or other countries.\n\n*If your glucose alerts and readings from the G6 or G7 CGM Systems do not match symptoms or expectations or you’re taking over the recommended maximum dosage amount of 1000mg of acetaminophen every 6 hours, use a blood glucose meter to make diabetes treatment decisions.\n\n  * [Privacy Policy](https://www.dexcom.com/linked/documentservice/PrivacyPolicy)\n  * [Terms of Use](https://www.dexcom.com/linked/documentservice/TermsOfUse)\n\n\n\n© 2024 Q4 Inc. - All rights reserved \n\n[ Powered By Q4 Inc. 5.140.1.1 (opens in new window) ](https://www.q4inc.com/Powered-by-Q4/)\n"
        }
      ]
    }
  ]
}